SOZO

ImpediMed is a global medical technology company specializing in non-invasive clinical assessment and monitoring of fluid status and tissue composition using bioimpedance spectroscopy (BIS). Its flagship product, the SOZO Digital Health Platform, is the world's first FDA-cleared BIS solution for the clinical assessment of lymphedema and is also utilized for monitoring heart failure and renal failure patients. The platform delivers real-time, actionable insights in under 30 seconds, enabling clinicians to detect subclinical changes and intervene early to improve patient outcomes. ImpediMed's technology is widely adopted by major healthcare systems and is used by pharmaceutical partners like AstraZeneca to track fluid outcomes in clinical trials.